vida: extract claims from 2024-12-05-ihme-us-life-expectancy-stall-2050-obesity-structural

- Source: inbox/queue/2024-12-05-ihme-us-life-expectancy-stall-2050-obesity-structural.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s.md

@@ -73,4 +73,10 @@ Topics:
 
 **Source:** Papanicolas et al., JAMA Internal Medicine 2025
 
-Drug-related deaths contributed 71.1% of the increase in preventable avoidable deaths from external causes during 2009-2019, providing precise quantification of the deaths-of-despair mechanism's contribution to US mortality divergence. The study shows this operated across all 50 states with West Virginia experiencing the worst increase (+99.6 per 100,000) while even the best-performing state (New York, -4.9) could not escape the broader deterioration pattern.
+Drug-related deaths contributed 71.1% of the increase in preventable avoidable deaths from external causes during 2009-2019, providing precise quantification of the deaths-of-despair mechanism's contribution to US mortality divergence. The study shows this operated across all 50 states with West Virginia experiencing the worst increase (+99.6 per 100,000) while even the best-performing state (New York, -4.9) could not escape the broader deterioration pattern.
+
+## Extending Evidence
+
+**Source:** IHME GBD 2050 Forecast, December 2024
+
+IHME's 2050 forecast projects drug use disorder death rates will increase 34% from 19.9/100K (2022) to 26.7/100K (2050), suggesting the structural socioeconomic drivers persist even as acute fentanyl supply disruptions temporarily reduce mortality in 2024. The model treats 2024's fentanyl decline as cyclical rather than structural resolution.

domains/health/Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated.md

@@ -1,23 +1,14 @@
 ---
-description: Market incentives drive food companies to maximize addictiveness through armies of food scientists and psychologists while government subsidizes the resulting health crisis -- chronic disease now kills more than famine infectious disease and war combined
 type: claim
 domain: health
-source: "Architectural Investing, Ch. Dark Side of Specialization; Moss (Salt Sugar Fat); Perlmutter (Brainwash)"
+description: Market incentives drive food companies to maximize addictiveness through armies of food scientists and psychologists while government subsidizes the resulting health crisis -- chronic disease now kills more than famine infectious disease and war combined
 confidence: proven
+source: Architectural Investing, Ch. Dark Side of Specialization; Moss (Salt Sugar Fat); Perlmutter (Brainwash)
 created: 2026-02-28
-related_claims:
-  - ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway
-  - upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure
-  - food-insecurity-creates-bidirectional-reinforcing-loop-with-cvd-through-medical-costs-and-dietary-quality
-  - hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause
-  - hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022
-related:
-- famine disease and war are products of the agricultural revolution not immutable features of human existence and specialization has converted all three from unforeseeable catastrophes into preventable problems
-reweave_edges:
-- famine disease and war are products of the agricultural revolution not immutable features of human existence and specialization has converted all three from unforeseeable catastrophes into preventable problems|related|2026-03-31
-- The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24
-supports:
-- The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment
+related_claims: ["ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway", "upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure", "food-insecurity-creates-bidirectional-reinforcing-loop-with-cvd-through-medical-costs-and-dietary-quality", "hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause", "hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022"]
+related: ["famine disease and war are products of the agricultural revolution not immutable features of human existence and specialization has converted all three from unforeseeable catastrophes into preventable problems", "Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated"]
+reweave_edges: ["famine disease and war are products of the agricultural revolution not immutable features of human existence and specialization has converted all three from unforeseeable catastrophes into preventable problems|related|2026-03-31", "The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24"]
+supports: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment"]
 ---
 
 # Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated
@@ -58,4 +49,10 @@ Relevant Notes:
 
 Topics:
 - health and wellness
-- livingip overview
+- livingip overview
+
+## Supporting Evidence
+
+**Source:** IHME GBD 2050 Forecast, December 2024
+
+IHME forecasts 260 million Americans will be affected by obesity by 2050, with obesity accelerating biological aging by more than 2 years in nonsmoking adults and slowing life expectancy gains while widening racial health disparities. This represents the long-run structural trajectory of the obesity epidemic.

domains/health/mdma-assisted-therapy-functional-unblinding-invalidates-self-reported-outcomes-despite-phase3-efficacy.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: FDA's 10-1 advisory committee vote against MDMA-AT approval despite positive Phase 3 efficacy establishes that pronounced psychoactive effects create structural methodological failure
+confidence: proven
+source: FDA Complete Response Letter to Lykos Therapeutics, August 9, 2024; FDA PDAC Advisory Committee vote June 4, 2024
+created: 2026-05-10
+title: MDMA-assisted therapy's FDA rejection reveals that clinical efficacy is necessary but insufficient for regulatory approval when functional unblinding invalidates self-reported outcomes in psychiatry trials
+agent: vida
+sourced_from: health/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md
+scope: structural
+sourcer: FDA / Psychiatric Times / STAT News
+related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software"]
+---
+
+# MDMA-assisted therapy's FDA rejection reveals that clinical efficacy is necessary but insufficient for regulatory approval when functional unblinding invalidates self-reported outcomes in psychiatry trials
+
+The FDA rejected Lykos Therapeutics' MDMA-assisted therapy for PTSD despite statistically significant Phase 3 efficacy (MAPP1 and MAPP2 trials showed CAPS-5 score reductions). The rejection centered on functional unblinding: MDMA's pronounced empathogenic and euphoric effects mean participants reliably know whether they received active drug or placebo. The FDA Psychopharmacologic Drugs Advisory Committee voted 10-1 that functional unblinding compromised trial validity—essentially unanimous agreement that MDMA trials cannot use inert placebo controls. This is a STRUCTURAL problem, not fixable through protocol modifications. The FDA explicitly required an additional Phase 3 study, indicating the existing evidence base was methodologically invalid despite clinical benefit. The contrast with psilocybin is instructive: Compass Pathways used 1mg as active placebo comparator (visually and experientially distinct from 25mg therapeutic dose) rather than inert placebo, and their Phase 3 trials passed FDA scrutiny. The divergence reveals that regulatory success depends not just on efficacy but on trial methodology that preserves outcome validity. For psychiatry trials relying on self-reported outcomes, functional unblinding creates systematic bias that invalidates results regardless of true clinical benefit.

domains/health/psychedelic-therapy-regulatory-success-requires-active-comparator-or-objective-endpoints-for-highly-psychoactive-compounds.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: The MDMA rejection versus psilocybin approval pathway divergence establishes that trial design must account for psychoactive intensity—inert placebo fails for pronounced effects
+confidence: likely
+source: FDA MDMA CRL August 2024; Compass Pathways Phase 3 design using 1mg active comparator
+created: 2026-05-10
+title: Psychedelic therapy regulatory approval requires either active comparator designs or objective endpoints because highly psychoactive compounds create functional unblinding that invalidates self-reported psychiatric outcomes
+agent: vida
+sourced_from: health/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md
+scope: structural
+sourcer: FDA / Psychiatric Times / STAT News
+---
+
+# Psychedelic therapy regulatory approval requires either active comparator designs or objective endpoints because highly psychoactive compounds create functional unblinding that invalidates self-reported psychiatric outcomes
+
+The FDA's rejection of MDMA-assisted therapy while psilocybin trials advance reveals a critical design constraint: the intensity of psychoactive effects determines viable trial methodology. MDMA produces pronounced empathogenic and euphoric effects that make functional unblinding inevitable with inert placebo—participants know they received the drug. The FDA advisory committee's 10-1 vote established this as disqualifying for self-reported psychiatric outcomes. In contrast, Compass Pathways' psilocybin trials used 1mg as active comparator (producing some perceptual effects) versus 25mg therapeutic dose, addressing the blinding concern through dose differentiation rather than inert placebo. This design choice allowed psilocybin trials to pass FDA scrutiny that MDMA trials failed. The implication generalizes: any highly psychoactive compound faces the same structural challenge. Future trials must either use active comparators that preserve some degree of blinding, or shift to objective endpoints (biomarkers, clinician-rated outcomes, behavioral measures) that are less vulnerable to expectancy bias. The functional unblinding problem is not solvable through protocol refinements—it requires fundamental redesign of trial architecture based on the compound's psychoactive profile.

domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md

@@ -10,20 +10,18 @@ agent: vida
 scope: structural
 sourcer: American Heart Association
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care]]"]
-supports:
-- Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden
-- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation
-- US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden
-- Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement
-reweave_edges:
-- Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden|supports|2026-04-07
-- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation|supports|2026-04-07
-- US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden|supports|2026-04-07
-- Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement|supports|2026-04-10
-sourced_from:
-- inbox/archive/health/2026-01-21-aha-2026-heart-disease-stroke-statistics-update.md
+supports: ["Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden", "Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation", "US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden", "Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement"]
+reweave_edges: ["Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden|supports|2026-04-07", "Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation|supports|2026-04-07", "US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden|supports|2026-04-07", "Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement|supports|2026-04-10"]
+sourced_from: ["inbox/archive/health/2026-01-21-aha-2026-heart-disease-stroke-statistics-update.md"]
+related: ["us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening", "us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements", "us-cardiovascular-mortality-gains-reversing-after-decades-of-improvement-across-major-conditions", "hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022", "hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause"]
 ---
 
 # US CVD mortality is bifurcating with ischemic heart disease declining while heart failure and hypertensive disease reach all-time highs revealing that aggregate improvement masks structural deterioration in cardiometabolic health
 
-The AHA 2026 report reveals a critical bifurcation in CVD mortality trends. While overall age-adjusted CVD mortality declined 33.5% from 1999 to 2023 (350.8 to 218.3 per 100,000), this aggregate improvement conceals opposing trends by disease subtype. Ischemic heart disease and cerebrovascular disease mortality both declined consistently over the study period. However, heart failure mortality reached an all-time high of 21.6 per 100,000 in 2023—exceeding even its 1999 baseline of 20.3 after declining to 16.9 in 2011. Hypertensive disease mortality doubled from 15.8 to 31.9 per 100,000 between 1999-2023, making hypertension the #1 contributing cardiovascular cause of death since 2022, surpassing ischemic heart disease. This pattern indicates that healthcare has become excellent at treating acute ischemic events (MI, stroke) through procedural interventions while simultaneously failing to address the upstream cardiometabolic drivers (obesity, hypertension, metabolic syndrome) that determine long-term healthspan. The bifurcation explains why life expectancy can improve (fewer people dying acutely) while population health deteriorates (more people living with chronic disease burden).
+The AHA 2026 report reveals a critical bifurcation in CVD mortality trends. While overall age-adjusted CVD mortality declined 33.5% from 1999 to 2023 (350.8 to 218.3 per 100,000), this aggregate improvement conceals opposing trends by disease subtype. Ischemic heart disease and cerebrovascular disease mortality both declined consistently over the study period. However, heart failure mortality reached an all-time high of 21.6 per 100,000 in 2023—exceeding even its 1999 baseline of 20.3 after declining to 16.9 in 2011. Hypertensive disease mortality doubled from 15.8 to 31.9 per 100,000 between 1999-2023, making hypertension the #1 contributing cardiovascular cause of death since 2022, surpassing ischemic heart disease. This pattern indicates that healthcare has become excellent at treating acute ischemic events (MI, stroke) through procedural interventions while simultaneously failing to address the upstream cardiometabolic drivers (obesity, hypertension, metabolic syndrome) that determine long-term healthspan. The bifurcation explains why life expectancy can improve (fewer people dying acutely) while population health deteriorates (more people living with chronic disease burden).
+
+## Extending Evidence
+
+**Source:** IHME GBD 2050 Forecast, December 2024
+
+IHME projects ischemic heart disease death rates declining 49.4%, stroke 40.5%, and diabetes 35.7% from 2022-2050, yet overall US life expectancy gains stall at 2.1 years over 28 years. This suggests cardiovascular improvements are being offset by obesity and drug mortality, with the US falling from 49th to 66th globally.

domains/health/us-life-expectancy-projected-stall-2050-obesity-drug-mortality-offset-cvd-gains.md

@@ -0,0 +1,25 @@
+---
+type: claim
+domain: health
+description: "IHME's 2050 forecast shows structural health threats (260M obese Americans, 34% increase in drug deaths) will limit US gains to 2.1 years over 28 years while peer nations improve faster"
+confidence: experimental
+source: IHME Global Burden of Disease 2050 Forecast, December 2024
+created: 2026-05-10
+title: US life expectancy is projected to stall at 80.4 years by 2050 while global ranking drops from 49th to 66th as obesity epidemic and drug mortality resurgence offset cardiovascular improvements
+agent: vida
+sourced_from: health/2024-12-05-ihme-us-life-expectancy-stall-2050-obesity-structural.md
+scope: structural
+sourcer: IHME
+supports: ["Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s", "Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated"]
+related: ["Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s", "Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated", "us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening", "us-healthspan-declining-while-lifespan-recovers-creating-divergence", "cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths", "us-cardiovascular-mortality-gains-reversing-after-decades-of-improvement-across-major-conditions", "us-healthspan-lifespan-gap-largest-globally-despite-highest-spending"]
+---
+
+# US life expectancy is projected to stall at 80.4 years by 2050 while global ranking drops from 49th to 66th as obesity epidemic and drug mortality resurgence offset cardiovascular improvements
+
+IHME's Global Burden of Disease 2050 forecast projects US life expectancy will reach only 80.4 years by 2050, up from 78.3 in 2022—a gain of just 2.1 years over 28 years. More significantly, the US global ranking will drop from 49th to 66th as other nations improve faster. This stall occurs despite projected improvements in cardiovascular mortality: ischemic heart disease deaths declining 49.4%, stroke 40.5%, and diabetes 35.7% from 2022-2050.
+
+The structural threats offsetting these gains are obesity and drug mortality. IHME forecasts 260 million Americans will be affected by obesity by 2050, with obesity accelerating biological aging by more than 2 years in nonsmoking adults. Drug use disorder death rates are projected to increase 34% from 19.9 per 100K (2022) to 26.7 per 100K (2050)—the highest rate globally, more than twice Canada's rate.
+
+This forecast provides critical context for the 2024 CDC life expectancy all-time high of 79.0 years. The IHME model treats the 2024 improvement as partially cyclical (COVID dissipation plus fentanyl supply disruption) rather than structural resolution. The divergence between acute mortality improvement (CDC 2024) and structural disease burden trajectory (IHME 2050) suggests the binding constraints on US healthspan remain obesity-driven metabolic disease and socioeconomic drivers of drug mortality, even as acute cardiovascular care improves.
+
+The global ranking decline is particularly revealing: it indicates the US is not declining absolutely but failing to address structural risk factors as effectively as peer nations. The 2050 projection assumes current policy trajectories continue—it does not account for potential GLP-1 scale effects, major policy reforms, or fentanyl supply dynamics that could alter the trajectory.

entities/health/lykos-therapeutics.md

@@ -0,0 +1,56 @@
+# Lykos Therapeutics
+
+**Type:** Pharmaceutical company (formerly MAPS Public Benefit Corporation)
+**Focus:** MDMA-assisted therapy for PTSD
+**Status:** Post-CRL restructuring (75% staff reduction as of August 2024)
+
+## Overview
+
+Lykos Therapeutics (formerly the public benefit corporation arm of MAPS - Multidisciplinary Association for Psychedelic Studies) developed MDMA-assisted therapy for post-traumatic stress disorder. The company conducted pivotal Phase 3 trials (MAPP1 and MAPP2) that showed statistically significant reductions in PTSD symptoms measured by CAPS-5 scores.
+
+## Regulatory History
+
+### FDA Complete Response Letter (August 9, 2024)
+
+The FDA rejected Lykos's New Drug Application for MDMA-assisted therapy, citing:
+
+1. **Functional unblinding:** MDMA's pronounced psychoactive effects (empathogenic, euphoric) meant participants could reliably identify whether they received active drug or placebo, biasing self-reported outcomes. The FDA Psychopharmacologic Drugs Advisory Committee voted 10-1 that functional unblinding compromised trial validity.
+
+2. **Data reliability concerns:** Systematic documentation issues for abuse-related adverse events and site oversight problems at clinical trial sites.
+
+3. **Cardiovascular risk:** Acute cardiovascular effects (heart rate and blood pressure elevation) raised safety concerns for broader population use.
+
+4. **Insufficient duration data:** Inadequate data to guide clinicians on duration of MDMA's therapeutic effects.
+
+The FDA required an additional Phase 3 study. No resubmission timeline has been announced as of May 2026.
+
+### FDA Advisory Committee Review (June 4, 2024)
+
+- **Benefit-risk vote:** 8-1 adverse
+- **Functional unblinding vote:** 10-1 adverse (essentially unanimous that blinding failure invalidated trial methodology)
+
+## Organizational Impact
+
+- Laid off approximately 75% of staff following the Complete Response Letter
+- Separated operations from MAPS PBC (nonprofit parent organization)
+- Meeting with FDA to request reconsideration and discuss resubmission pathway
+
+## Clinical Trial Program
+
+**Phase 3 Trials:**
+- MAPP1 and MAPP2 showed statistically significant PTSD symptom reductions
+- Used inert placebo comparator (later identified as methodological flaw)
+- Efficacy demonstrated but methodology deemed invalid by FDA
+
+## Timeline
+
+- **2024-06-04** — FDA Psychopharmacologic Drugs Advisory Committee votes 10-1 against approval based on functional unblinding concerns
+- **2024-08-09** — FDA issues Complete Response Letter rejecting NDA, requiring additional Phase 3 study
+- **2024-08** — Lykos lays off ~75% of staff following CRL
+- **2025-09-04** — Complete Response Letter made public
+
+## Sources
+
+- FDA Complete Response Letter, August 9, 2024
+- Psychiatric Times coverage, September 2025
+- STAT News reporting, October 2025

entities/health/maps-pbc.md

@@ -0,0 +1,23 @@
+# MAPS Public Benefit Corporation
+
+**Type:** Nonprofit public benefit corporation
+**Parent:** Multidisciplinary Association for Psychedelic Studies (MAPS)
+**Focus:** Psychedelic-assisted therapy development
+**Status:** Separated from Lykos Therapeutics operations (2024)
+
+## Overview
+
+MAPS Public Benefit Corporation was the nonprofit pharmaceutical development arm of MAPS (Multidisciplinary Association for Psychedelic Studies), a 40+ year organization pioneering psychedelic therapy research. MAPS PBC created Lykos Therapeutics to advance MDMA-assisted therapy through FDA approval.
+
+## Organizational Structure
+
+MAPS PBC operated as the parent organization to Lykos Therapeutics, maintaining nonprofit status while conducting pharmaceutical development. Following the FDA Complete Response Letter in August 2024, MAPS PBC and Lykos separated operations.
+
+## Timeline
+
+- **2024-08** — Separated operations from Lykos Therapeutics following FDA Complete Response Letter
+
+## Sources
+
+- Psychiatric Times, September 2025
+- STAT News, October 2025

inbox/archive/health/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md

@@ -7,10 +7,13 @@ date: 2024-08-09
 domain: health
 secondary_domains: []
 format: regulatory-document
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-10
 priority: medium
 tags: [MDMA, PTSD, FDA, complete-response-letter, Lykos-Therapeutics, MAPS, clinical-trial, functional-unblinding, psychedelic-therapy]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2024-12-05-ihme-us-life-expectancy-stall-2050-obesity-structural.md

@@ -7,10 +7,13 @@ date: 2024-12-05
 domain: health
 secondary_domains: []
 format: research-report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-10
 priority: medium
 tags: [life-expectancy, IHME, GBD, 2050-forecast, obesity, metabolic-disease, drug-use, structural-health, US-global-ranking, chronic-disease]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content